NYU Langone Research Leads to Accelerated Approval of Bladder … – PR Newswire (press release)
PR Newswire (press release) |
NYU Langone Research Leads to Accelerated Approval of Bladder …
PR Newswire (press release) NEW YORK, April 20, 2017 /PRNewswire-USNewswire/ — Findings from a clinical trial led by a researcher at NYU Langone’s Perlmutter Cancer Center helped … |
Regulatory Focus |
Regulatory Recon: Uniqure to Abandon Gene Therapy in EU; Pfizer Subpoenaed Over Saline Shortages (20 April 2017)
Regulatory Focus Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. Want to read Recon as soon as it’s posted? Follow @RAPSorg on Twitter. In Focus: US. The High Cost of Prescription Drugs in the United States (JAMA); HHS to … |
FiercePharma |
The world’s most pricey drugs, from a $1.2M gene therapy to a $450K lymphoma med
FiercePharma It’s a gene therapy, the first to win a regulatory nod, and on the leading edge of a potential wave of therapies of that ilk, many costing upwards of $1 million or more. Payers and other experts, worried about their advent, have been tossing around … |
|
ARMO BioSciences Announces Clinical Data Presentations for Immunotherapy AM0010 at ASCO 2017 Annual Meeting
Yahoo Finance REDWOOD CITY, Calif., April 20, 2017 /PRNewswire/ — ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced that five abstracts with clinical data on the Company’s lead investigational immuno-oncology drug AM0010 … |
|
ARMO BioSciences Announces Clinical Data Presentations for Immunotherapy AM0010 at ASCO 2017 Annual Meeting
Yahoo Finance REDWOOD CITY, Calif., April 20, 2017 /PRNewswire/ — ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced that five abstracts with clinical data on the Company’s lead investigational immuno-oncology drug AM0010 … |
NBCNews.com |
Firm Pulls World’s First Gene Therapy Treatment: No One Wants It
NBCNews.com The biotech company behind the Western world’s first gene therapy and the most expensive prescription medicine in history is giving up on the product because of lack of demand. Only one patient has been treated commercially since the $1 million … UniQure to Yank Pioneering Gene Therapy From Market in EuropeXconomy Goodbye Glybera! The World’s First Gene Therapy will be WithdrawnLabiotech.eu (blog) UniQure Says It Will Not Pursue EC Marketing Renewal for Glybera Gene TherapyGenetic Engineering & Biotechnology News (blog) Seeking Alpha –FiercePharma –pharmaphorum all 11 news articles » |